<DOC>
	<DOCNO>NCT01765283</DOCNO>
	<brief_summary>The purpose study assess safety appraise efficacy one cycle Hepastem ( Heterologous Human Adult Liver-derived Progenitor Cells , HHALPC ) infusion paediatric patient suffer CN UCD . The study duration : 12 month start day treatment : 6 month active surveillance 6 month observation post-infusion .</brief_summary>
	<brief_title>Safety Study HepaStem Treatment Urea Cycle Disorders ( UCD ) Crigler-Najjar Syndrome ( CN )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Urea Cycle Disorders , Inborn</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Crigler-Najjar Syndrome</mesh_term>
	<criteria>GENERAL : 1 . Subject show patency portal vein branch , normal flow velocity main portal vein confirm Doppler ultrasound accessibility portal vein , respectively , accessibility umbilical vein . 2 . Subject ( capable signing ) parent legal representative provide write informed assent/consent . 3 . Female subject childbearing potential need negative pregnancy test must agree use acceptable method contraception throughout study . MAIN INCLUSION CRITERIA CriglerNajjar Syndrome specific : Patient present CriglerNajjar syndrome type 1 . Patient present CriglerNajjar syndrome type 2 , poorly control phenobarbital treatment , experience serious impairment quality life . Diagnosis must confirm genetic mutation analysis available . Urea Cycle Disorders specific : Diagnosis one urea cycle disorder disease severity warrant liver transplantation alternative despite full conservative therapy , subject experience serious impairment quality life despite full conservative therapy . MAIN EXCLUSION CRITERIA The subject 18 year old time screen . The subject present acute liver failure , clinical radiological evidence liver fibrosis cirrhosis , present history hepatic extrahepatic malignancy The patient noncorrected cardiac malformation , know medical family history coagulopathy , renal insufficiency treat dialysis . The subject require valproate therapy . The subject thrombosis portal vein persist impairment anterograde portal blood flow . The subject porto systemic shunt fistula assess Doppler US . Patients disease severity liver transplantation absolute indication .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>CN ,</keyword>
	<keyword>UCD</keyword>
</DOC>